

Clofibrate

Catalog No: tcsc2300



Available Sizes

Size: 1g

Size: 5g



Specifications

CAS No:

637-07-0

Formula:

$C_{12}H_{15}ClO_3$

Pathway:

Cell Cycle/DNA Damage

Target:

PPAR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (412.03 mM); H₂O :

Observed Molecular Weight:

242.7

Product Description


Clofibrate is an agonist of **PPAR**, with **EC₅₀**s of 50 μ M, \sim 500 μ M for murine PPAR α and PPAR γ , and 55 μ M, \sim 500 μ M for human PPAR α and PPAR γ , respectively.

IC₅₀ & Target: EC₅₀: 50 μ M (Murine PPAR α), \sim 500 μ M (Murine PPAR γ), 55 μ M (Human PPAR α), \sim 500 μ M (Human PPAR γ)^[1]

In Vitro: Clofibrate is a PPAR agonist, with E₅₀s of 50 μ M, \sim 500 μ M for murine PPAR α and PPAR γ , and 55 μ M, \sim 500 μ M for human

PPAR α and PPAR γ , respectively^[1]. Clofibrate (0.5, 1, 2 mM) increases FABP1 expression in two fatty acid (FA)-treated rat hepatoma cells. Clofibrate lowers ROS levels after early treatment, much more than late treatment in FA-treated cells^[2].

In Vivo: Clofibrate (0.5%) up-regulates serum concentrations and hepatic expression of FGF21 in fetuses, with a return to basal levels after Clofibrate administration withdrawal. Clofibrate administration-offspring have significantly higher expression of thermogenic genes (Ucp1, Cidea, Ppara Ppargc1a, Cpt1b) and UCP1 protein levels in response to HFD in inguinal fat, but not in retroperitoneal (combined with perirenal) or epididymal fat^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!